GlassScriptPhysician profile
Amanda C Guidon
NPI 1639344583
$88,251.23
in general payments reported to CMS, 2019-2025
9 companies · $30K in 2025
The $30K reported for 2025 was more than what 94% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $6,330 · 2021: $7,268 · 2022: $11K · 2024: $33K · 2025: $30K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $61K · Travel and Lodging: $1,655 · Food and Beverage: $833.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $60,895.00 |
| Travel and Lodging | $1,654.85 |
| Food and Beverage | $832.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $43,000.81 | 2022-2025 | Rystiggo, Zilbrysq |
| Alexion Pharmaceuticals, INC. | $28,816.30 | 2020-2024 | Ultomiris, Soliris |
| Ucb Sa | $8,000.00 | 2025 | Rystiggo |
| Amgen INC. | $3,512.50 | 2025 | Uplizna |
| Janssen Research & Development, LLC | $2,250.00 | 2020 | |
| Argenx US, INC. | $2,187.50 | 2024 | Vyvgart |
| Regeneron Pharmaceuticals, INC. | $484.12 | 2024 | Libtayo |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amanda Guidon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.